These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28466570)

  • 41. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):18-9. PubMed ID: 25768998
    [No Abstract]   [Full Text] [Related]  

  • 44. A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma.
    Bertrand KA; Giovannucci E; Zhang SM; Laden F; Rosner B; Birmann BM
    Cancer Prev Res (Phila); 2013 Aug; 6(8):864-73. PubMed ID: 23803416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.
    Bendtsen MD; Munksgaard PS; Severinsen MT; Bekric E; Brieghel C; Nielsen KB; Brown PN; Dybkaer K; Johnsen HE; Bøgsted M; El-Galaly TC
    Eur J Haematol; 2017 Apr; 98(4):355-362. PubMed ID: 27893172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
    Al-Mansour M; Connors JM; Gascoyne RD; Skinnider B; Savage KJ
    J Clin Oncol; 2010 Feb; 28(5):793-9. PubMed ID: 20048177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Park S; Han B; Cho JW; Woo SY; Kim S; Kim SJ; Kim WS
    Nutr Cancer; 2014; 66(2):225-33. PubMed ID: 24405259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
    Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.
    Graff-Baker A; Roman SA; Thomas DC; Udelsman R; Sosa JA
    Surgery; 2009 Dec; 146(6):1105-15. PubMed ID: 19958938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Results of cytostatic therapy of malignant hemoblastoses].
    Stacher A
    Wien Z Inn Med; 1966 Jan; 47(1):1-16. PubMed ID: 4962311
    [No Abstract]   [Full Text] [Related]  

  • 56. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Body mass index and risk of malignant lymphoma in Scandinavian men and women.
    Chang ET; Hjalgrim H; Smedby KE; Akerman M; Tani E; Johnsen HE; Glimelius B; Adami HO; Melbye M
    J Natl Cancer Inst; 2005 Feb; 97(3):210-8. PubMed ID: 15687364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study.
    Geyer SM; Morton LM; Habermann TM; Allmer C; Davis S; Cozen W; Severson RK; Lynch CF; Wang SS; Maurer MJ; Hartge P; Cerhan JR
    Cancer; 2010 Jun; 116(12):2993-3000. PubMed ID: 20564404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fungating groin mass in a woman with a history of follicular lymphoma.
    Bailoor K; Chen T
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28814600
    [No Abstract]   [Full Text] [Related]  

  • 60. Body size and risk of non-Hodgkin lymphoma by subtype: A pooled analysis from six prospective cohorts in the United States.
    Teras LR; Bertrand KA; Deubler EL; Chao CR; Lacey JV; Patel AV; Rosner BA; Shu YH; Wang K; Zhong C; Wang SS; Birmann BM
    Br J Haematol; 2022 Jun; 197(6):714-727. PubMed ID: 35348212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.